z-logo
open-access-imgOpen Access
Retrospective analysis of the efficacy of percutaneous transhepatic biliary drainage in palliation of obstructive jaundice in patients with carcinoma gall bladder: Experience from tertiary care center in Northern India
Author(s) -
Milind Sawant,
Srinivasan Harish,
Nishant Lohia,
Sury Anand,
Manoj Prashar,
Sankalp Singh,
Gaurav Trivedi
Publication year - 2021
Publication title -
asian journal of medical sciences
Language(s) - English
Resource type - Journals
ISSN - 2091-0576
DOI - 10.3126/ajms.v12i11.38761
Subject(s) - medicine , jaundice , percutaneous , malignancy , surgery , retrospective cohort study , obstructive jaundice , biliary drainage , bladder cancer , tertiary care , percutaneous transhepatic cholangiography , complication , cancer
Background: Percutaneous Transhepatic Biliary Drainage (PTBD) is a minimally invasive procedure to palliate the biliary obstruction caused by unresectable malignancy.Aims and Objective: To analyze the outcome of PTBD in patients of unresectable gall bladder cancer presenting with obstructive jaundice in terms of reduction in serum bilirubin levels, symptomatic improvement, and overall survival (OS) at 4 weeks and 12 weeks following the procedure.Materials and Methods: In this retrospective study, PTBD was attempted on 30 patients diagnosed with inoperable gall bladder cancer. Various patient and procedure-related variables were analyzed and recorded both pre and post-PTBD. Outcome data on OS was collected at 4 weeks and 12 weeks.Results: Technical success was achieved in 29 (99.66%) patients. The mean fall in the serum bilirubin at the 7th post-procedural day was 41.5% after the successful PTBD. The most common complication in our study was cholangitis noted in six (21%) patients. OS at 4 weeks and 12 weeks was 79% and 41%, respectively.Conclusion: Younger age and good performance status favored better survival rate in our study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here